100.4  -3.28 (-3.16%)		02-11 16:00
Open: 103.74 High: 104.115 Volume: 467,885		Pre. Close: 103.68 Low: 98.045 Market Cap: 3,914(M)

Short term
Mid term
Targets	6-month :	127.27	1-year :	138.8
Resists	First :	108.96	Second :	118.83
Pivot price	102.84
Supports	First :	93	Second :	77.37
MAs	MA(5) :	99.72	MA(20) :	102.19
	MA(100) :	87.67	MA(250) :	56.86
MACD	MACD :	0.7	Signal :	1.3
%K %D	K(14,3) :	32	D(3) :	28
RSI	RSI(14): 50.1
52-week	High :	118.83	Low :	20.44

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ GRAL ] has closed above bottom band by 37.9%. Bollinger Bands are 21.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	104.17 - 104.71	104.71 - 105.11
Low:	96.93 - 97.46	97.46 - 97.88
Close:	99.54 - 100.45	100.45 - 101.15

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

Tue, 10 Feb 2026
GRAIL Inc (GRAL) Shares Up 5.15% on Feb 10 - GuruFocus

Sun, 08 Feb 2026
GRAIL submits FDA PMA for Galleri multi-cancer early detection test - MSN

Sun, 08 Feb 2026
Moloney Securities Asset Management LLC Has $959,000 Stock Holdings in GRAIL, Inc. $GRAL - MarketBeat

Sun, 08 Feb 2026
GRAIL, Inc. $GRAL Shares Purchased by Allianz Asset Management GmbH - MarketBeat

Fri, 06 Feb 2026
What GRAIL (GRAL)'s FDA PMA Submission for Galleri Test Means For Shareholders - Sahm

Mon, 02 Feb 2026
GRAIL Inc (GRAL) Shares Up 3.77% on Feb 2 - GuruFocus

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	39 (M)
Shares Float	33 (M)
Held by Insiders	10.2 (%)
Held by Institutions	65.5 (%)
Shares Short	5,370 (K)
Shares Short P.Month	4,730 (K)

EPS	-10.33
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	61.93
Profit Margin	-286.5 %
Operating Margin	-346.2 %
Return on Assets (ttm)	-11.1 %
Return on Equity (ttm)	-16.9 %
Qtrly Rev. Growth	26.2 %
Gross Profit (p.s.)	-1.73
Sales Per Share	3.63
EBITDA (p.s.)	-8.97
Qtrly Earnings Growth	0 %
Operating Cash Flow	-329 (M)
Levered Free Cash Flow	-59 (M)

PE Ratio	-9.72
PEG Ratio	0
Price to Book value	1.62
Price to Sales	27.59
Price to Cash Flow	-11.91

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.